您现在的位置是:f s o s h h u j 1 t w i c c a z h i 8 s s z 8 t s a e > Leisure
【will peppermint oil kill lice】Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
f s o s h h u j 1 t w i c c a z h i 8 s s z 8 t s a e2024-09-29 08:11:43【Leisure】1人已围观
简介Cytokinetics (CYTK) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Est will peppermint oil kill lice
Cytokinetics (CYTK) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.42. This will peppermint oil kill licecompares to loss of $0.48 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -23.81%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.56 per share when it actually produced a loss of $0.50, delivering a surprise of 10.71%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Cytokinetics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $5.21 million for the quarter ended December 2019, missing the Zacks Consensus Estimate by 27.51%. This compares to year-ago revenues of $9.38 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Cytokinetics shares have added about 34.2% since the beginning of the year versus the S&P 500's decline of -4.4%.
What's Next for Cytokinetics?
While Cytokinetics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Cytokinetics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.48 on $7 million in revenues for the coming quarter and -$2.03 on $27.80 million in revenues for the current fiscal year.
Story continues
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
View comments
很赞哦!(71711)
相关文章
- Used Construction Equipment Market to hit USD 142 Bn by 2026: Global Market Insights, Inc.
- 10 Block, a Tech Startup Recognized by SXSW 2019, is Releasing a Universal TV Series and Movie Discovery Platform So You Can See What Your Friends Like
- Equitrans Midstream Corporation (ETRN) Stock Moves -1.99%: What You Should Know
- TUI Will Cut Budgets, Freeze Hiring to Deal With Coronavirus Spread
- EMERGING MARKETS-Latam stocks weaken as risk rally pauses
- Nokia draws $560 million R&D loan for 5G
- U.S. Stocks Set To Open Higher On Final Day Ahead Of U.S. Presidential Election
- A Sliding Share Price Has Us Looking At Rexnord Corporation's (NYSE:RXN) P/E Ratio
- 35 Surprising Cities With Low Costs of Living
- Portugal says unacceptable to block EU recovery funds
热门文章
站长推荐
Russia's Ozon wants dual listing in Moscow and U.S. -sources
Suzan Craig and Tahi Restore Nature and Make 100 Percent Natural, Genuine Honey
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results
From wagyu beef to melons, Japan's $2.2 trillion virus rescue piques struggling firms
Imagine Owning ImmunoPrecise Antibodies (CVE:IPA) And Wondering If The 44% Share Price Slide Is Justified
Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties
Canadian General Investments: Investment Update - Unaudited
IMPORTANT APRIL DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MGP Ingredients, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
友情链接
- Japan April final manufacturing PMI falls to 49.9 on soft domestic, export orders
- Tesla shares drop on price cut, disappointing Model 3 deliveries
- Top Money Moves I’m Making Now To Save My Bank Account in 2021
- Could The HKBN Ltd. (HKG:1310) Ownership Structure Tell Us Something Useful?
- Michael B. Jordan Eulogizes Chadwick Boseman: “I Now Understand How Much of a Legend and Hero YOU Are”
- Banks and tech will finally get married in the 2020s: Wells Fargo's Mike Mayo
- BRIEF-Eurocrane China's Shareholder To Unload Up To 5 Pct Stake Between March 4 And Aug 1
- Facebook Rises 3%
- REPEAT-Second Annual BMO Volunteer Day: BMO Employees in Vancouver and Across North America Give Back to the Community
- PayPoint plc : Total voting rights